Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
about
NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppressionMechanical disruption of tumors by iron particles and magnetic field application results in increased anti-tumor immune responsesSystemic IL-12 administration alters hepatic dendritic cell stimulation capabilitiesImmune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagentWEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.Identification of novel compounds that enhance colon cancer cell sensitivity to inflammatory apoptotic ligands.Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapyChallenges and future perspectives of T cell immunotherapy in cancerBortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Cooperativity of adaptive and innate immunity: implications for cancer therapy.Fas expression by tumor stroma is required for cancer eradication.Immunotherapy of MHC class I-deficient tumors.Targeting the extrinsic apoptosis signaling pathway for cancer therapy.Modification of Antitumor Immunity and Tumor Microenvironment by Resveratrol in Mouse Renal Tumor Model.Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models.Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas.Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.
P2860
Q28268202-23596FF5-8F9A-4918-BBC5-84492248DAA0Q28390368-1AE3A0BC-337E-40A5-8738-0EB2BDFEA0F8Q28512535-6B6DF972-A877-4EB5-82DA-1DFA2BCE2561Q28648083-F4829D9C-89AA-4DB2-B0F2-D2893842DC5AQ33570786-AD385F2D-6CD7-411C-87D3-B75BD50A3024Q34573226-8E1ADD57-C250-42F2-9F06-1A2941242273Q35721553-62CB882B-508C-4E0D-BB4A-DC99735F0258Q35843507-D84F3D79-4AF9-4425-A767-54BE31FCA470Q36378038-942944EF-E30D-4C78-BB82-3C615CF1A765Q36429508-D08DF950-DFC0-4030-A054-C9FFA29AFF1BQ36598412-6FDC18FB-0B52-4A76-9967-D793B6209144Q37808218-C52F9A50-4C3E-4F32-8EE6-0020FC512DBCQ37882480-F5DCAEE7-9057-44E7-94A0-89E86F455867Q38918196-1DAEF547-0E98-4795-926B-EB3681D1FB4CQ42288675-096AB731-2351-45EF-9E50-10E03060FE3BQ44249895-2CD0117A-A81A-4984-B377-35BC038D609DQ45512143-F288A9B9-BCBD-4ECF-994B-83CC9CE638DB
P2860
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
@en
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
@nl
type
label
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
@en
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
@nl
prefLabel
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
@en
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
@nl
P2093
P2860
P1433
P1476
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
@en
P2093
Alan D Brooks
John W Wine
Kristen M Jacobsen
Robert H Wiltrout
Thomas J Sayers
P2860
P304
P356
10.1158/0008-5472.CAN-09-0685
P407
P577
2009-08-04T00:00:00Z